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Abstract: Liquid biopsy is a rapidly emerging tool of precision oncology enabling minimally
invasive molecular diagnostics and longitudinal monitoring of treatment response. For the clinical
management of advanced stage lung cancer patients, detection and quantification of circulating
tumor DNA (ctDNA) is now widely adopted into clinical practice. Still, interpretation of results and
validation of ctDNA-based treatment decisions remain challenging. We report here our experience
implementing liquid biopsies into the clinical management of lung cancer. We discuss advantages
and limitations of distinct ctDNA assay techniques and highlight our approach to the analysis
of recurrent molecular alterations found in lung cancer. Moreover, we report three exemplary
clinical cases illustrating the complexity of interpreting liquid biopsy results in clinical practice.
These cases underscore the potential and current limitations of liquid biopsy, focusing on the difficulty
of interpreting discordant findings. In our view, despite all current limitations, the analysis of ctDNA
in lung cancer patients is an essential and highly versatile complementary diagnostic tool for the
clinical management of lung cancer patients in the era of precision oncology.
Keywords: liquid biopsy; lung cancer; resistance mechanisms; targeted therapy
1. Introduction: State of the Art and Uses of Liquid Biopsy in Lung Cancer
Liquid biopsy is an increasingly relevant diagnostic tool in the management of patients with lung
cancer [1]. This method is based on detection of circulating cancer cell markers in liquid samples,
predominantly plasma. Such markers include circulating free DNA (cfDNA), circulating tumor DNA
(ctDNA), exosomes, circulating tumor cells (CTCs), microRNAs, as well as antigens and antibodies
derived from cancer cells [2]. Nowadays, liquid biopsy is mainly used in lung cancer for patients
with metastatic disease in order to monitor response or to detect emerging resistance mechanisms,
while further uses such as early tumor detection are still under investigation [3,4]. Over the last
years, an increasing number of clinical trials in lung cancer have incorporated the use of liquid biopsy,
in addition to tissue genomic testing. However, still limited data are available correlating results
from liquid biopsies with response to molecularly targeted treatment or resistance. Different assays
J. Clin. Med. 2020, 9, 3674; doi:10.3390/jcm9113674 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 3674 2 of 19
can be used, such as real-time polymerase chain reaction (PCR), digital droplet PCR (ddPCR),
and next-generation sequencing (NGS) [5,6]. For the most frequently targeted genes in lung cancer,
such as EGFR, a high concordance rate of more than 90% has been shown between alterations detected
in liquid biopsy and matched tissue samples [7,8]. However, less frequent genomic alterations lack such
standardization. Additionally, the analytical sensitivity is variable, depending on the implemented
assay [9]. Our work reports a series of controversial clinical cases and reviews related literature data.
2. Available Assays and Target Genomic Alterations in Lung Cancer
2.1. Liquid Biopsy Assays
For genomic profiling of lung cancer, several assays, which can be used in clinical routine and for
research purposes, are available to date. This leads to a broad spectrum of alternatives (Table 1) to
evaluate the most common genes of interest: EGFR, ALK, BRAF, KRAS, NRAS, MET, ERBB2, ROS1,
and NTRK (Table 2).
Table 1. Liquid biopsy assays with main advantages and limitations. Abbreviations: ddPCR:
digital droplet PCR.
Assay Type Advantages Main Limitations
Real-time PCR
-Rapid results
-Cost effectiveness
-Limited number of DNA sequences
-Allele frequency of at least 1% for some assays
(Cobas® EGFR Mutation Test v2, Therascreen)
Digital droplet PCR
-High sensitivity (detection of low
allele frequency, 0.005–0.1%)
-Limited number of DNA sequences
Next-generation sequencing
-Larger number of DNA sequences
-Detection of coexisting mutations
-Higher allele frequency required compared to
ddPCR (0.1%)
-Higher costs
-More complex data analysis and interpretation
2.1.1. Real-Time PCR
During real-time PCR, also designed as quantitative PCR (qPCR), specific DNA or complementary
DNA (cDNA) sequences undergo amplification and thermal cycling, with measurement of obtained
DNA quantity after completion of each cycle. Main advantages of qPCR are the speed and cost
effectiveness, as compared to other techniques. Single nucleotide variants (SNVs), deletions, fusions,
or markers of DNA methylation can be detected [10]. As disadvantages, only limited DNA sequences
can be analyzed in the same reaction. Additionally, the limits of detection and limits of quantification
vary depending on the calibration of the assay used [11]. If Therascreen or the cobas® kits are used,
usually an allele frequency of at least 1% is required due to high rate of false negative results [10].
The cobas® EGFR Mutation Test v2, approved by FDA in 2016, is a real-time PCR assay that interrogates
42 mutations within EGFR exons 18, 19, 20, and 21, including the resistance mutation p. T790M,
as well as the less common exon 20 p. S768I and exon 21 p. L861Q mutations [12]. In the phase
III ENSURE trial [13], which evaluated the efficacy and safety of first-line erlotinib as compared to
chemotherapy with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer
(NSCLC) harboring an EGFR activating mutation, plasma samples were collected from 517 patients.
In parallel to tissue biopsy analysis, cobas® EGFR Mutation Test v2 was used to assess the presence of
EGFR activating mutations in plasma. In patients without mutations of EGFR (Del19 and p. L858R),
the liquid biopsy resulted negative in 98.2% of cases (95% confidence interval (CI): 95.4–99.3%)
as compared with tissue testing. In patients with tumors harboring an EGFR mutation, however,
sensitivity of the plasma tests was only 76.7% (95% CI: 70.5–81.9%). Based on this trial, the cobas® EGFR
Mutation Test v2 received FDA approval for plasma testing of EGFR Del19 and p. L858R mutations
in order to identify patients eligible for treatment with erlotinib. However, it was specified in the
approval that patients with negative liquid biopsy results should undergo tissue testing. Additionally,
in the ENSURE trial, detection of cfDNA for EGFR Del19 and p. L858R mutations positively correlated
with progression-free survival (PFS) [13].
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Table 2. Main target genes and mutations in non-small cell lung cancer (NSCLC) and summary of most frequently used liquid biopsy assays used for their assessment.
Abbreviations: ddPCR: digital droplet PCR; NGS: next-generation sequencing; RT-PCR: real-time PCR; * e.g., Oncomine™ Lung cfDNA Assay, FoundationOne®
Liquid CDx, GUARDANT360®, InVisionFirst®-Lung).
Target Genomic Alteration
Most Frequent
Liquid Biopsy Assays
Relevant Features
EGFR
Del19 and p. L858R RT-PCR
-Cobas® EGFR Mutation Test v2
-IdyllaTM ctEGFR Mutation Test
-EntroGen ctEGFR Mutation Detection Kit
-Cobas®: 79% concordance with positive tissue test (FLAURA trial)
p. T790M
RT-PCR
-Cobas® EGFR Mutation Test v2
-IdyllaTM ctEGFR Mutation Test
-EntroGen ctEGFR Mutation Detection Kit
-Cobas®: 51% concordance with positive tissue test (AURA3 trial)
-Relevance of tissue rebiopsies in case of negative plasma test
Droplet Digital™ PCR
-71% vs. 41% sensitivity, 83% vs. 100% specificity as compared to
Cobas®, and 74% concordance with tissue test (AURA trial, 38 samples)
BEAMing digital PCR
-81% vs. 73% sensitivity, 58% vs. 67% specificity as compared to Cobas®
(AURA trial, 72 samples)
NGS *
-For GUARDANT360® 70-gene NGS: 85% concordance with positive
tissue test (Therascreen EGFR RGQ PCR Kit, Qiagen)
p. C797S
RT-PCR (EntroGen ctEGFR Mutation Detection Kit)
ddPCR or NGS*
ALK Fusions and mutations
RT-PCR
-From plasma or platelets (65–79% sensitivity, higher for platelets;
89–100% specificity)
NGS * -Allows identification of distinct fusion partners
MET
Exon 14 skipping and
amplifications
ddPCR or NGS *
-ddPCR for MET amplification: 86% sensitivity and 100% specificity as
compared with positive tissue FISH
BRAF Mutations
RT-PCR
-Competitive Allele-Specific TaqMan® PCR
-29% sensitivity, 93% specificity, and 89% concordance as compared with
positive tissue test
-IdyllaTM ctBRAF Mutation Test
ddPCR or NGS *
ROS1 Fusions and mutations NGS * -InVisionFirst®-Lung: 67% sensitivity for ROS1/ALK fusions at diagnosis
RET Fusions and mutations NGS * -Allows identification of distinct fusion partners
KRAS Mutations RT-PCR, ddPCR, or NGS *
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In the pooled population of the AURA2 study, a phase 2 trial that evaluated the safety and efficacy
of osimertinib in the second-line setting for patients harboring the p. T790M resistance mutation [14],
liquid biopsy sampling with analysis of cfDNA was performed. cfDNA was analyzed with cobas®
EGFR Mutation Test v2 and compared with available tissue biopsies. For the EGFR p. T790M mutation,
the liquid biopsy test had a sensitivity of 61% (95% CI: 57–66%), a specificity of 79% (95% CI: 70–85%),
and a concordance of 65% (95% CI: 61–69%), as compared to the tissue assay. For the EGFR Del19 and
p. L858R mutations, the sensitivity was of 85% and 76%, the specificity of 98% for both mutations,
and the concordance with tissue biopsy was 90% and 91%, respectively [15].
As part of a comparative study evaluating the quality of assessment of EGFR mutations in plasma,
across seven Korean laboratories, the level of detection (LOD) of the cobas® EGFR Mutation Test v2
was assessed. LOD was of 5–27 copies/mL for the EGFR Del19 mutation, 35–70 copies/mL for the
pL858R mutation, and 18–36 copies/mL for the resistance p. T790M mutation [9].
Other assays based on real-time PCR are IdyllaTM ctEGFR Mutation Assay, covering 49 mutations in
the same four exons of EGFR (18–21), as well as Therascreen EGFR RGQ PCR Kit v2, testing 29 mutations.
The Therascreen EGFR RGQ PCR Kit v2 has been implemented in the LUX-Lung 3 and 6 trials for
assessment of a total of 287 serum and 334 plasma samples from patients harboring an EGFR mutation.
In the LUX-Lung 3 study, the Therascreen detected EGFR mutations in 28.6% of the cases. This detection
rate was higher (60.5%) in the LUX-Lung 6 trial [16].
2.1.2. Digital Droplet PCR
DdPCR improves quantification of amplified DNA sequences by dispersing the sample in uniform
droplets [17,18]. The major advantage of this technique is the increased sensitivity, which enables
the detection of as low allele fractions as 0.005 –0.1% [19,20]. A comparative study evaluated the
performance of ddPCR, real-time PCR, and MALDI-TOF mass spectrometry in detecting EGFR
p. T790M mutations in tissue biopsies. Additionally, the three methods were compared with results
of ultradeep NGS using SiRe®. ddPCR and NGS could more frequently identify positive cases with
very low mutant-allele frequencies (ranging from 0.07% to 0.38%) [21]. Similarly to real-time PCR,
a disadvantage of ddPCR is the limited number of mutant DNA sequences that can be analyzed within
one assay.
2.1.3. Next-Generation Sequencing
NGS allows to screen simultaneously multiple genes, requiring, however, the presence of a higher
allele frequency, as compared to ddPCR [22,23]. OncomineTM Lung cfDNA Assay is an NGS-based
liquid biopsy assay that interrogates the most frequent mutations in NSCLC across eleven genes.
With a LOD between 0.1% and 1% of allele frequency, the assay showed a sensitivity of 87.5% and a
specificity of 100% for hotspot mutations. For an allele frequency of 0.1%, sensitivity of the assay was
of 91.7% for point mutations, being lower (75%) for detection of indels. For the same allele frequency,
specificity was 100% for both point mutations and indels [23].
GUARDANT360® Circulating Tumor DNA Assay is another NGS-based test with coverage of
54–73 genes, depending on the version of the test. For SNVs, the GUARDANT360® 73 gene-panel
has a sensitivity of 100% with a positive predictive value (PPV) of 99.2% for an allele frequency
of ≥0.25%, and a sensitivity of 63.8% with a PPV of 96.3% for an allele frequency of 0.05–0.25%.
As compared to tissue NGS analysis, plasma assessment with GUARDANT360®, pooled with results
from FoundationOne® Liquid CDx assay, showed a concordance between 91% and 94.2%, however,
in a cohort of 45 patients with breast cancer [24].
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2.2. Target Genomic Alterations
2.2.1. EGFR Del19 and p. L858R Mutations
The FLAURA phase 3 study compared first-line osimertinib to gefitinib or erlotinib in patients
with locally advanced or metastatic NSCLC harboring an activating EGFR mutation. In FLAURA,
the plasma cobas® EGFR Mutation Test v2 was retrospectively used to assess the presence of the EGFR
Del19 and p. L858R mutation in plasma and compared to the tissue testing results. From a cohort of
211 patients with centrally confirmed positive tissue EGFR mutational status, 79% had a concordant
positive liquid biopsy results with plasma cobas® EGFR Mutation Test. Interestingly, PFS was longer
in both treatment arms (osimertinib and gefitinib/erlotinib) in patients with negative cfDNA for EGFR
mutations (23.5 and 15.0 months, respectively). Moreover, patients with positive cfDNA analysis
showed a shorter PFS (15.2 and 9.7 months, respectively) [25]. These data underline the predictive
value of cfDNA for EGFR-targeted treatments.
2.2.2. EGFR p. T790M Mutation
The p. T790M mutation of the EGFR gene is the main resistance mechanism to first and second
generation EGFR-TKIs [26,27]. The liquid biopsy with the cobas® EGFR Mutation Test v2 performed
in 419 patients from the AURA3 trial showed that the concordance with tissue biopsies was lower for
the EGFR p. T790M mutation than for the other EGFR activating mutations (51% for p. T790M, 82% for
Del19, and 68% for p. L858R) [28] This underscored the relevance of performing tissue rebiopsies in
case of negative plasma results at tumor progression, where a p. T790M is suspected. A meta-analysis
reviewing eleven studies using ddPCR for detection of the EGFR p. T790M mutation in cfDNA
reported a global sensitivity and specificity in the pooled analysis of 70.1% (95% CI: 62.7–76.7%) and
86.9% (95% CI: 80.6–91.7%), respectively (1). In a comparative evaluation of different assays used
for detection of the EGFR p. T790M mutation in plasma samples from the AURA trial, the authors
compared in 38 samples the cobas® EGFR Mutation Test, the Therascreen™ EGFR amplification
refractory mutation system assay, and two digital assays: Droplet Digital™ PCR and BEAMing digital
PCR. The two digital platforms showed a better performance. In the subsequent direct comparison
between cobas® EGFR Mutation Test and BEAMing digital PCR in 72 additional plasma samples,
the sensitivity of the cobas® EGFR Mutation Test for detection of the p. T790M mutation was of
73%, as compared to the 81% obtained by BEAMing digital PCR. The specificity was of 67% and 58%,
respectively, and the concordance between the 2 platforms of 90% [29].
In the liquid biopsy assessment of the p. T790M mutation performed as part of the TIGER-X
and TIGER-2 trials, which evaluated the safety and efficacy of rociletinib, a third-generation EGFR
TKI, in patients with EGFR mutant lung cancers progressing after first-line TKI, the GUARDANT360®
70-gene NGS panel was used to analyze cfDNA. While primary EGFR activating mutations were
identified in 93% of the cases, the resistance mutation p. T790M could be detected only in 85% of
positive matching tissue samples (Therascreen EGFR RGQ PCR Kit, Qiagen) [30].
In a systematic meta-analysis evaluating the accuracy of ctDNA-based assays to investigate the
detection of the p. T790M mutation, a total of 21 studies up to 2018 were reviewed, including 1639 patients.
Digital PCR was the most frequently implemented technique, used in 12 out of 21 studies, followed by
real-time PCR in 6 studies. NGS was performed in 3 out of 21 studies. The pooled analysis showed
a global sensitivity for ctDNA analysis of 0.67 (95% CI: 0.64–0.70), with a pooled specificity of 0.80
(95% CI: 0.77–0.83). The global PPV was 0.85 (95% CI: 0.82–0.87), and the negative predictive value
(NPV) was 0.60 (95% CI: 0.56–0.63) [31].
2.2.3. EGFR p.C797S Mutation
The emergence of the resistance mutation p.C797S in exon 20 of the EGFR gene constitutes one of
the major acquired resistance mechanisms to osimertinib [32]. This mutation could be detected using
NGS, followed by targeted ddPCR assays, in cfDNA of NSCLC patients treated within the AURA phase
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I trial. When performing ddPCR cfDNA analysis in resistant tumors, distinct mutational scenarios
have been detected: occurrence of the p.C797S mutation, persistence of the p. T790M mutation
without addition of p.C797S, and loss of p. T790M with persistence of the initial EGFR mutation [33].
Using cfDNA NGS, the concomitant detection of the original EGFR activating mutation together with
p. T790M and p.C797S has been reported at progression under treatment with third-generation TKI [34].
Interestingly, the type of resistance mutation has shown to be specific for the inhibitor used: the p.
L798I mutation has been reported under treatment with rociletinib, and, while approximately a third
of patients under osimertinib showed the p. C797S resistance mutation, this was only detected in 2%
of patients treated with rociletinib [35]. Additionally, some RT-PCR-based assays, such as EntroGen
ctEGFR Mutation Detection Kit, also enable the detection of this mutation. Although no effective
targeted treatment for this resistance mutation is yet available, its detection is gaining relevance since
third-generation EGFR inhibitors have become standard for up-front treatment of EGFR-mutated
NSCLC [36].
2.2.4. ALK
Different liquid biopsy methods can be used to assess the presence of ALK rearrangements in
lung cancer patients. Real-time PCR was used in a cohort of 77 patients with NSCLC to detect ALK
rearrangements. In plasma, the specificity of the assay was 100%, with a sensitivity of 21%. In platelets,
the sensitivity increased to 65%, maintaining the 100% of specificity [37]. The lower sensitivity observed
for the plasma test could be related to the lower stability of circulating RNA in plasma as compared to
RNA extracted from platelets [31].
In a study using real-time PCR to assess ALK status in lung cancer, 33 ALK-positive and 28
ALK-negative patients, assessed by fluorescent in situ hybridization (FISH) break-apart, were enrolled.
Plasma, platelets, and tumor tissue were used for RNA extraction and cDNA synthesis. Results of
liquid biopsy showed a higher sensitivity (78.8%), specificity (89.3%), and accuracy (83.6%) for detection
of ALK rearrangements, as compared to the formalin-fixed paraffin-embedded (FFPE) tissue analysis,
with 54.5% sensitivity, 78.6% specificity, and 75.5% accuracy. Liquid biopsy was more frequently
positive in patients with later sampling, defined as 6 months or later following diagnosis of lung
cancer. In the subgroup of 26 patients treated with the ALK-TKI inhibitor crizotinib, patients with
platelet-positivity for ALK rearrangements had a longer treatment duration (7.2 versus 1.5 months),
median PFS (5.7 versus 1.7 months) and higher response rates (70.6% versus 11.1%) [38].
From a GUARDANT360® database of NSCLC liquid biopsies, several ALK fusion partners
could be identified: EML4 (85.4%), STRN (6%), as well as KCNQ, KLC1, KIF5B, PPM1B, and TGF.
Additionally, liquid biopsies from 31 patients had been analyzed upon tumor progression under ALK
inhibition. Resistance alterations could be detected in 16 cases (53%), finding a number of 1–3 resistance
mutations. Moreover, in 6 patients who had an initial EGFR activating mutation, the presence of an
ALK rearrangement could be detected at progression [39].
In the Phase II/III blood first assay screening (BFAST) trial, 2.219 patients with advanced (stage IIIB
or IV) NSCLC underwent FoundationOne® Liquid CDx assay in order to identify actionable genomic
alterations. ALK rearrangements were found in 119 patients (5.4%), and 87 out of 119 received treatment
with alectinib. This subgroup showed an objective response rate of 87.4% (95% CI: 78.5–93.5%), with a
response rate of 75.9% (95% CI: 63.6–88.2%) at 12 months and a median investigator-assessed PFS of
78.4% (95% CI: 69.1–87.7%) [40].
2.2.5. MET
MET exon 14 skipping mutations and MET amplifications [41] predict response to targeted treatment
with MET inhibitors, such as crizotinib [42], capmatinib [43,44], both FDA approved for NSCLC harboring
MET exon 14 skipping mutations [45], or tepotinib [46,47]. Additionally, MET alterations can emerge as
resistance mechanisms to other molecularly targeted agents [48].
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As a consequence of the liquid biopsy testing in the FLAURA3 trial, distinct molecular aberrations
could be uncovered as resistance events to treatment with osimertinib. These alterations included MET
amplifications (15%), EGFR p.C797S mutation (7%), HER2-amplifications, as well as PIK3CA and RAS
mutations (2–7%) [2].
DdPCR has been used to detect MET copy number alterations in cfDNA in a prospective study
including 174 patients with several cancers, most frequently in metastatic stage. Concentration of
plasma cfDNA correlated significantly with MET copy number. Additionally, MET amplifications
were determined in CTCs, and longitudinal monitoring of both parameters, cfDNA and MET in CTCs,
was performed during ongoing treatment with anti-EGFR therapy, as MET overexpression might
also contribute to resistance to these drugs. As assessed by the Parsortix system, the presence of
MET-positive CTCs (≥1) correlated with poorer overall survival in patients with head and neck cancers
(HR = 6.66, p = 0.05). MET amplification assessment had a concordance of 91.67%, as compared with
tissue biopsies evaluation by FISH (ratio MET/CEN−7 > 4). Plasma ddPCR had a sensitivity of 85.71%,
as compared to tissue analysis, and a specificity of 100% [49].
In a comprehensive assessment of ctDNA from 1552 NSCLC patients, using hybrid capture-based
genomic profiling, MET exon 14 skipping mutations were detected in 1.9% of cases. Moreover,
additional activating SNVs of MET (p. L1195V, p. D1228H, and p. Y1230C) could be detected in three
cases [50].
In a study analyzing the presence of MET alterations in ctDNA, assessed with NGS using
GUARDANT360®, 438 patients with several solid tumors were screened. Additionally, in 263 patients
matching tissue NGS, covering 182–315 genes, was performed. Here, 71.2% of patients had recurrent
or metastatic disease, and the most frequent cancer types analyzed were gastrointestinal (28.1%),
brain (24.9%), and lung tumors (23.2%). In addition, 31 patients (7.1%) showed alterations in MET,
which correlated in a multivariant analysis with presence of bone metastases (p = 0.007), as well as
concomitant aberrations in TP53 (p = 0.001) and PTEN (p = 0.003). Additionally, a shorter median
time to metastasis or tumor recurrence was found to be associated with presence of MET alterations
(1.0 vs. 10.4 months, p = 0.044), as well as a shorter overall survival (30.6 vs. 58.4 months, p = 0.013).
Tissue biopsies were available and screened for MET alterations in only 18 out of the 31 patients.
Interestingly, these were found only in two tissue biopsies, so that the authors concluded that ctDNA
was more sensitive for detection of MET alterations, and associated with poorer prognosis in the
analyzed population [51].
2.2.6. BRAF
The activating BRAF p. V600E mutation is present in approximately 1–2% of NSCLC patients [52].
The presence of the p. V600E mutation sensitizes to treatment with combinations of BRAF and
MEK-TKIs [52,53]. In a case series of six patients with known BRAF p. V600E mutated NSCLC,
cfDNA and CTCs were analyzed for the BRAF p. V600E mutation. Detection was performed using
ddPCR, which identified the mutation in all six samples of cfDNA, however, only in one out of six
samples extracted from CTCs [54]. In a study evaluating the performance of Competitive Allele-Specific
TaqMan® PCR (CastPCR) for detection of driver oncogenic mutations in plasma cfDNA from patients
with lung adenocarcinoma, 107 patients were included, and plasma samples, as well as paired
tissue biopsies, were collected. Using CastPCR, plasma samples were screened for the presence of
EGFR and BRAF mutations. For the BRAF mutations (c.1406G>C p. G469A, c.1799T>A p. V600E,
c.1781A>G p. D594G), the liquid biopsy test showed a sensitivity of 28.6% (2/7), a specificity of 93.0%
(93/100), a concordance with the tissue detection of 88.8% (95/107), a PPV of 22.2% (2/9), and a NPV of
94.9% (93/98) [55].
In a case report, plasma from a patient with an EGFR-mutated advanced lung adenocarcinoma
with initial response to osimertinib, followed by development of resistance and progressive disease,
was analyzed with ddPCR. Liquid biopsy samples, as well as paired tissue samples, were interrogated
for the presence of resistance mutations, such as EGFR p. T790M, EGFR p. C797S, BRAF p. V600E,
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MET amplification, and HER2 amplification. The BRAF p. V600E mutation could be detected
as resistance mechanism at time point of tumor progression under treatment with osimertinib.
Additionally, the initial EGFR Del19 and p. T790M mutations could be further detected, illustrating the
persistence of the initial subclone [56].
2.2.7. ROS1
ROS1 rearrangement can be found in approximately 1% of NSCLC patients [57], predicting response to
TKIs, such as crizotinib [58], ceritinib [59], lorlatinib [60], entrectinib [61], or repotrectinib [62]. In a study
including 128 patients with known ALK or ROS1 alterations, liquid biopsy samples underwent genomic
profiling using the InVisionFirst®-Lung, a ctDNA NGS platform assessing 37 genes. Of these patients,
101 had a known rearrangement in ALK and the other 27 in ROS1. For detection of fusions in ALK or
ROS1, and at time point of diagnosis, the NGS assay showed a sensitivity of 67%. ALK rearrangement
could be more frequently detected in patients progressing under TKI treatment, as compared to patients
with response (46% vs. 11%). Resistance mutations to ALK inhibitors could be identified in 22% of
patients, being ALK p. G1202R, the most frequently detected mutation. The ROS1 p. G2032R resistance
mutation was found in 30% of evaluated cases. Patients with no detectable mutations in ctDNA had a
longer median overall survival despite progression on TKIs [63].
2.2.8. RET
RET rearrangements are found in 1–2% of patients with NSCLC [64], conferring potential therapeutic
vulnerability to several TKIs, such as selpercatinib [65] or praseltinib [66]. In a comprehensive genomic
analysis using GUARDANT360®, cfDNA of 32.989 patients with metastatic solid cancers was analyzed.
Specifically, 176 RET alterations were found in 170 patients, corresponding 143 to fusions and 33 to
missense mutations. Moreover, 125 patients out of 170 had NSCLC, followed by colorectal, breast,
thyroid, and other cancers. KIF5B-RET fusions were found to be highly specific for NSCLC. The study
also showed that patients with RET fusion partners distinct from KIF5B, exhibited also enrichment for
alterations in the MAPK pathway and EGFR [67].
2.2.9. KRAS
KRAS oncogenic mutations are present in 25–35% of NSCLC [68,69]. In a cohort of 194 patients,
assessment of KRAS mutational status has been performed through a ctDNA plasma NGS analysis
(SiRe®). KRAS mutations were detected in 18.6% of the screened cases, and for these patients, no further
concomitant mutations have been found in EGFR, NRAS, BRAF, KIT, or PDGFRA. Moreover, 36.1% of
the detected mutations corresponded to the currently targetable p. G12C KRAS mutation [70,71].
However, KRAS mutations can also coexist with further “targetable” oncogenic alterations [72–74].
Such presence of concomitant alterations to KRAS can be also used as a “positive control” of liquid
biopsies. The only detection of KRAS in liquid biopsies can be of further use for longitudinal molecular
monitoring of disease [75,76].
3. Case Series: Challenges of the Use of Liquid Biopsy in Daily Management of Lung Cancer Patients
3.1. Case 1
A 60-year-old male patient, never-smoker, was referred with the suspicion of metastatic NSCLC in
June 2017. The initial staging with 18F-fluorodeoxyglucose positron emission/computed tomography
(18FDG-PET/CT) showed a primary tumor in the right upper lobe and multiple bone metastases in the
spine and right acetabulum (Figure 1a). The histological analysis of the primary tumor showed an
adenocarcinoma expressing TTF-1, harboring the EGFR exon 21 p. L858R mutation.
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Figure 1. (a). 18F-fluorodeoxyglucose positron emission/computed tomography (18FDG-PET/CT)
scan performed before start of treatment; the arrows show the primary tumor in the lung and
some of the bone metastases. (b). 18FDG-PET/CT scan performed after 3 months of treatment
with erlotinib and bevacizumab. The arrows show partial remission of the primary tumor and the
bone metastases. (c). 18FDG-PET/CT scan performed after 9 months of treatment with erlotinib and
bevacizumab. The blue arrows show the slight progression of the primary tumor and in the sacrum.
(d). 18FDG-PET/CT in January 2019. The blue arrows show new diffuse bone metastasis of several
skeletal regions and the red arrow a new pleural lesion, which was biopsied.
The initial stage according to the TNM 8th Edition was cT1pN1cM1c (stage IVB). The patient started
on treatment with erlotinib and bevacizumab, based on the results of the BELIEF study [77], as well as
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received radiotherapy to the symptomatic bone metastases in the spine and acetabulum. Additionally,
antiresorptive treatment with monthly denosumab was initiated. The restaging 18FDG-PET/CT after
3 months of treatment showed a partial remission of the primary tumor and bone metastases (Figure 1b).
Nevertheless, 9 months from treatment initiation, a slight progression of the primary tumor and
appearance of new bone metastases in the sacrum were detected (Figure 1c). A rebiopsy of the primary
tumor with targeted EGFR PCR using cobas® EGFR Mutation Test v2 was performed, which showed
the previously detected p. L858R mutation in exon 21 of EGFR and no other alterations.
The patient continued treatment with erlotinib and bevacizumab, but stereotactic radiotherapy
to the oligoprogressing primary tumor and sacrum was initiated. The patient continued to be in
partial remission until January 2019, when he presented with progressively increasing thoracic pain.
The restaging 18FDG-PET/CT showed new diffuse lytic bone lesions in several skeletal regions and a
new pleural lesion, with stable primary tumor (Figure 1d).
A transthoracic biopsy of the new pleural metastasis, as well as a plasma liquid biopsy using the
OncomineTM Lung cfDNA Assay was performed. Liquid biopsy showed no EGFR mutations but the
presence of the pathogenic BRAF p. V600E mutation. The biopsy of the pleural metastasis revealed an
infiltrate of lambda-restricted plasma cells with aberrant CD117, CD56, and CyclinD1 coexpression,
consistent with a plasmacytoma. Furthermore, the presence of the BRAF p. V600E mutation in the
pleural metastasis was confirmed, as well.
After further diagnostic work-up, including bone marrow examination, diagnosis of plasma cell
myeloma (syn. multiple myeloma) IgG lambda type was made, and the patient started treatment with
bortezomib, lenalidomide, and dexamethasone. The treatment with erlotinib for the metastatic NSCLC
was continued, with discontinuation of bevacizumab. Currently, the patient is still on partial remission
for both diseases (Figure 2).
Figure 2. Timeline of disease and treatment course in case 1.
3.2. Case 2
A 74-year-old female patient was diagnosed with lung adenocarcinoma with bilateral pulmonary
disease (cT2a N3 M1a, stage IVA according to the TNM 8th Edition) in December 2015. The molecular
analysis on tissue biopsy revealed the coexistence of a p. L858R mutation in exon 21 and an ab initio
p. T790M mutation in exon 20 of the EGFR gene. The patient started on treatment with osimertinib in
February 2016 achieving a partial response as best response by CT scan, with no significant toxicities.
In September 2017, asymptomatic bilateral pulmonary progression was detected. Liquid biopsy was
negative for EGFR p. T790M mutation as assessed by cobas® EGFR Mutation Test v2. In November 2017,
an atypical segmentectomy of the lower right lobe was performed. The biopsy showed a mixed
tumor with lepidic adenocarcinoma areas and small-cell lung cancer (SCLC). No EGFR mutations were
detected in the molecular analysis of the tumor specimen. Osimertinib was then discontinued and the
patient began treatment with carboplatin plus etoposide, with partial response.
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In March 2018, a new asymptomatic pulmonary progression was detected by CT scan.
Liquid biopsy with cobas® EGFR Mutation Test v2 was repeated showing the presence of an EGFR
p. T790M mutation. The patient refused treatment with osimertinib at that point. In August 2018,
respiratory symptoms (dyspnea and cough) were progressing, so that treatment with erlotinib and
bevacizumab was started.
A further pulmonary progression was detected by CT scan in October 2018. A plasma test with
cobas® EGFR Mutation Test v2 was performed, which showed the coexistence of p. L858R and
p. T790M EGFR mutations. With this result, treatment with osimertinib was reinitiated, with partial
response and no major toxicities. In April 2019, a new pulmonary and hepatic progression was detected
by CT scan. A hepatic biopsy was performed with the result of high-grade neuroendocrine carcinoma
with an ALK rearrangement detected by VENTANA ALK (D5F3) CDx Assay®. The coexistence
of p. L858R and p. T790M EGFR mutations was still detected by cobas® EGFR Mutation Test.
Treatment with alectinib was started in April 2019. One week after treatment initiation, the patient
died due to respiratory insufficiency and a syndrome of inappropriate antidiuretic hormone secretion
(SIADH) (Figure 3).
Figure 3. Timeline of disease and treatment course in case 2. Adenoca.: adenocarcinoma; mut.:
mutation; NGS: next-generation sequencing; PD: progressive disease; SCLC: small-cell lung cancer.
3.3. Case 3
A 65-year-old female patient was diagnosed with pleural metastatic lung adenocarcinoma in
November 2017. A p. L858R mutation in exon 21 of EGFR was detected in the pleural biopsy, so that the
patient started on treatment with erlotinib and bevacizumab in December 2017. Following morphologic
and metabolic response, the tumor progressed in the pleura about 20 months after treatment initiation.
A liquid biopsy with the OncomineTM Lung cfDNA Assay was performed, which revealed the
presence of the p. T790M EGFR resistance mutation, as well as the original p. L858R mutation.
Additionally, a pleural biopsy was performed, showing histologic transformation into SCLC. Hybrid
NGS using FoundationOne® CDx Test was performed on this biopsy revealing the presence of the
original EGFR p. L858R mutation, as well as RB1 loss, TP53 mutation, and RICTOR amplification,
among others. The patient started on cisplatin and etoposide in August 2019, achieving a partial
response in 18FDG-PET/CT scan performed in October 2019. At this point, liquid biopsy by OncomineTM
Lung cfDNA Assay showed the presence of the EGFR p. L858R mutation, but p. T790M and TP53
mutations could not be detected. The patient refused to receive further chemotherapy and a treatment
with osimertinib was started due to the presence of the EGFR p. T790M mutation at the first tumor
progression. The 18FDG-PET/CT scan performed 2 months after starting osimertinib and 3 months
after initial response showed tumor progression at different locations (pleura, lung, and lymph
nodes). Plasma test with OncomineTM Lung cfDNA Assay found the persistent EGFR p. L858R
mutation, as well as a new PIK3CA p. E545K mutation. A biopsy of the parasternal lymph node
metastasis showed SCLC. Chemotherapy with carboplatin and etoposide was, therefore, restarted in
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February 2020, and a new liquid biopsy by OncomineTM Lung cfDNA Assay reported the reappearance
of the known EGFR p. L858R mutation, without any additional findings. Last tumor assessment
revealed a mixed response with oligoprogression of lymph node metastases and new bone metastases.
The patient is currently undergoing local treatment with radiotherapy (Figure 4).
’
–
– –
Figure 4. Timeline of disease and treatment course in case 3. Ampl.: amplification; mut.: mutation;
PD: progressive disease; PR: partial response; SCLC: small-cell lung cancer.
4. Discussion
Unlike tissue-based tumor molecular analysis, liquid biopsy allows minimally invasive genomic
profiling and, if performed serially, may provide a more comprehensive information regarding global
tumor evolution occurring at different metastatic sites throughout the course of disease. Additionally,
liquid biopsy can be a useful tool for detection of emerging resistant tumor subclones [64,78,79].
However, the here reported clinical cases also illustrate the current limitations of liquid biopsy
as compared to the tumor rebiopsy. In case 1, in the absence of tumor tissue biopsy, the presence
of a BRAF mutation in cfDNA might have been interpreted as an underlying resistance mechanism
to the EGFR inhibition [80,81]. This solely information might have compromised the diagnosis and
treatment of multiple myeloma. However, the data proceeding from tissue and liquid biopsy can still
be complementary, especially for progressive and refractory diseases, where increasing molecular
tumor heterogeneity derived from coexisting distinct molecular subclones occurs.
This also underlines that the heterogeneity of assays might lead to major challenge, especially in
regard to the spectrum of covered mutations and analytical sensitivity of the different liquid biopsy
platforms. For this reason, the selection of the most optimal assay, as well as a comprehensive
interpretation of results, is crucial. To overcome such challenge, the access to a molecular tumor board
for multidisciplinary assessment of individual clinical situations and interpretation of obtained data
could be fundamental.
Since multiple liquid biopsy techniques are available (RT-PCR, ddPCR, and NGS), we give here
an overview of their main advantages and limitations (Table 1). The most frequently used assays for
common genomic alterations in NSCLC are summarized in Table 2.
A clear example of such variety of tests, is the development of multiple liquid biopsy techniques
and platforms to assess activating and resistance mutations in the EGFR gene. The complexity of data
interpretation derives not only from the broad spectrum of tests, but also from the different sensitivity,
specificity, and concordance with tissue-results of each assay. Even if the same platform is used,
variations of mutations can be detected when different patients’ populations are evaluated [82]. In a
cohort of 102 patients with EGFR mutant lung cancer, the real-time PCR by cobas® EGFR Mutation Test
v2 has shown a concordance for EGFR p. L858R and exon 19 deletion to matched tissue samples of 87.4%,
a sensitivity for detection of the EGFR mutations of 70.6%, and a specificity of 91.7%. Two additional
cohorts (n = 238 from the FASTACT-2 study and n = 196 published by Weber et al.), using cobas®
EGFR Mutation Test v2, reported a specificity of 96%, sensitivity of 60–75%, and a concordance with
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tissue biopsy of 88–91% [83–85]. NGS-based liquid biopsy assays, such as OncomineTM Lung cfDNA
Assay or GUARDANT360® Circulating Tumor DNA Assay, have shown sensitivities for detection of
covered genomic alterations ranging from 58% to 87%, with specificities up to 99–100% [86,87].
Moreover, a further limitation of the liquid biopsy is related to the possibility of sampling bias and
limited sensitivity of some assays. For example, the sensitivity for detection of the resistance p. T790M
EGFR mutation in liquid biopsies is lower when compared to the initial activating EGFR mutations [1],
and a tissue rebiopsy is still recommended when p. T790M is not detected in plasma, especially if the
initial activating EGFR mutation is also absent [82].
Despite the lower sensitivity, a potential advantage of NGS-based liquid biopsy assays could
be the simultaneous detection of other coexisting mutations, also when their presence has no direct
therapeutic consequence. This is the case of concurrent KRAS mutations [72–74], which, with the
exception of KRAS G12C [70,71], are currently not targetable. Their detection can, however, serve as a
positive sampling control and for disease course monitoring.
The cases 2 and 3 illustrate the importance of optimal assay selection for disease monitoring in
patients undergoing targeted treatment. In contrast to RT-PCR or ddPCR platforms, NGS-based assays
allow simultaneous screen and discovery of multiple possible resistance mechanisms, giving more
information about course of disease and, in our opinion, should be prioritized, whenever possible.
In this way, uncovered emerging resistance alterations may offer novel therapeutic opportunities
for personalized molecularly targeted treatment. In case 2, liquid biopsies during treatment with
osimertinib had been performed with cobas® EGFR Mutation Test v2, a RT-PCR assay, whereas liquid
biopsy NGS with OncomineTM Lung cfDNA Assay was used in case 3. In case 2, cobas® EGFR
Mutation Test v2 would have missed the emergence of the p.C797S mutation, one of the main resistance
mechanisms reported under treatment with third-generation EGFR TKIs, especially osimertinib [88].
However, some RT-PCR-based assays, such as EntroGen ctEGFR Mutation Detection Kit, do cover this
relevant resistance mutation. Though not yet drugable, the screening for the p.C797S mutation will
have an increasing relevance in the years, since treatment for third-line TKIs has moved to first-line
treatment for EGFR-mutated NSCLC [36].
Our third case illustrates the potential of liquid biopsy to be implemented as a noninvasive tool
for monitoring disease course and response or development of resistance to treatment, complementary
to imaging. In a very exhaustive manner, Rolfo et al. reviewed multiple available data regarding
the monitoring of the p. T790M EGFR mutation with different assays [82]. Its detection in plasma is
considered sufficient to switch the TKI treatment.
However, as for the second and third cases, liquid biopsy missed SCLC transformation and,
therefore, tissue biopsy is crucial when the liquid biopsy is not informative or histologic transformation
is suspected based on clinical or radiological discordance, in line with previously reported cases [89–91].
Interestingly, Minari et al. reported that a detected low ratio p. T790M/EGFR activating mutation in
liquid biopsy correlated with the presence of histological transformation to SCLC [91], which might be
useful whenever a tissue biopsy is not feasible.
In our review, we analyze the main pros and limitations of the distinct liquid biopsy assays,
underscoring the difficulty and the relevance of the optimal assay selection. Additionally, we present
the first reported case of a concomitant multiple myeloma diagnosis, uncovered through liquid biopsy
in a patient with NSCLC.
In summary, liquid biopsy is a rapidly developing minimally invasive diagnostic tool with great
potential to detect oncogenic drivers at baseline and along tumor evolution. However, this technique
has limitations that should be taken into account in the clinical practice. The complexity of results
interpretation entails the need of multidisciplinary approach.
5. Conclusions
Liquid biopsy has become an essential part of diagnostic genomic profiling and dynamic
monitoring of disease course in lung cancer, enabling a better characterization of the molecular
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heterogeneity and clonal evolution that emerges during tumor progression and as adaptive response
to targeted oncological treatment. Nevertheless, tissue biopsies still remain essential and provide
gold standard information regarding tumor molecular characterization and are especially necessary to
detect histologic transformation, which can occur in the setting of resistance to targeted therapy.
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